21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
23:31 , Oct 11, 2018 |  BC Week In Review  |  Company News

Philadelphia groups partner to target Tregs for lung cancer

AUM LifeTech Inc. (Philadelphia, Pa.), Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania partnered to develop an RNA silencing immunotherapy to treat lung cancer. The therapeutic, which...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
02:46 , Mar 24, 2018 |  BioCentury  |  Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
23:51 , Mar 19, 2018 |  BC Innovations  |  Translation in Brief

Crafting CAR Tregs

TxCell S.A. (Euronext:TXCL) thinks it has cracked the code on building CAR Tregs without running into the manufacturing challenges that can compromise the cells’ immunosuppressive function. The company presented data on their manufacturing process at...
00:04 , Feb 15, 2018 |  BC Innovations  |  Translation in Brief

Gut check

A Nature study from New York University has shown the T cell regulator MAF determines whether the intestinal immune system of mice responds to certain bacteria with a protective Treg population or a pro-inflammatory Th17...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
01:16 , Aug 11, 2017 |  BC Extra  |  Clinical News

Immunotherapy could slow progression of Type I diabetes

In a paper published in Science Translational Medicine , researchers at King’s College London and colleagues reported data from a Phase Ib trial suggesting that an antigen-specific peptide immunotherapy could slow the progression of Type...
07:00 , Jun 9, 2016 |  BC Innovations  |  Tools & Techniques

Entrez LA Cell

LA Cell Inc. is developing a new way of reaching the long sought-after goal of getting antibodies inside cells by chemically modifying the molecules. While the company believes it can expand the druggable universe of...